{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:24:41Z","timestamp":1778768681178,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T00:00:00Z","timestamp":1544313600000},"content-version":"am","delay-in-days":311,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.nano.2017.11.004","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:17:19Z","timestamp":1511223439000},"page":"317-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cell type-specific pharmacological kinase inhibition for cancer chemoprevention"],"prefix":"10.1016","volume":"14","author":[{"given":"Manjeet","family":"Deshmukh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Vincek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Ruiz de Galarreta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna P","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadassa","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C Billie","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"El-Abtah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor B","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaia","family":"Lujambio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan C","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaas","family":"Poelstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujin","family":"Hoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2017.11.004_bb0005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/23808993.2016.1174062","article-title":"Use of big data in drug development for precision medicine","volume":"1","author":"Kim","year":"2016","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"10.1016\/j.nano.2017.11.004_bb0010","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.nano.2017.11.004_bb0015","first-page":"1129","article-title":"Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges","volume":"12","author":"Hoshida","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.nano.2017.11.004_bb0020","doi-asserted-by":"crossref","first-page":"10262","DOI":"10.3748\/wjg.v21.i36.10262","article-title":"Molecular prognostic prediction in liver cirrhosis","volume":"21","author":"Goossens","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.nano.2017.11.004_bb0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2017.05.007","article-title":"Hepatic stellate cells as key target in liver fibrosis","volume":"121","author":"Higashi","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2017.11.004_bb0030","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.26898","article-title":"Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma","volume":"59","author":"Fuchs","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.nano.2017.11.004_bb0035","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.22886","article-title":"Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma","volume":"110","author":"Thomas","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.nano.2017.11.004_bb0040","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3727\/000000003108747064","article-title":"Establishment of an immortalized human hepatic stellate cell line to develop antifibrotic therapies","volume":"12","author":"Shibata","year":"2003","journal-title":"Cell Transplant"},{"key":"10.1016\/j.nano.2017.11.004_bb0045","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/gut.2004.042127","article-title":"Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis","volume":"54","author":"Xu","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.nano.2017.11.004_bb0050","doi-asserted-by":"crossref","first-page":"11307","DOI":"10.1073\/pnas.1000806107","article-title":"Structures of a platelet-derived growth factor\/propeptide complex and a platelet-derived growth factor\/receptor complex","volume":"107","author":"Shim","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2017.11.004_bb0055","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/hep.24395","article-title":"Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice","volume":"54","author":"Bansal","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.nano.2017.11.004_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0093-7754(03)70011-6","article-title":"Preclinical studies with Erlotinib (Tarceva)","volume":"30","author":"Akita","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.nano.2017.11.004_bb0065","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2362.1987.tb02198.x","article-title":"A light microscopic and biochemical study of carbon tetrachloride-induced pulmonary fibrosis in rats: the preventive effect of malotilate","volume":"17","author":"Paakko","year":"1987","journal-title":"Eur J Clin Investig"},{"key":"10.1016\/j.nano.2017.11.004_bb0070","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ccell.2016.11.004","article-title":"Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition","volume":"30","author":"Nakagawa","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.nano.2017.11.004_bb0075","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.nano.2017.11.004_bb0080","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","article-title":"Liver cirrhosis","volume":"371","author":"Schuppan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.nano.2017.11.004_bb0085","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.nano.2017.11.004_bb0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2017.02.007","article-title":"Poly-sgRNA\/siRNA ribonucleoprotein nanoparticles for targeted gene disruption","volume":"250","author":"Ha","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2017.11.004_bb0095","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/ncb3031","article-title":"EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation","volume":"16","author":"Lanaya","year":"2014","journal-title":"Nat Cell Biol"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963417301995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963417301995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:08:53Z","timestamp":1761548933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963417301995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1549963417301995"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2017.11.004","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cell type-specific pharmacological kinase inhibition for cancer chemoprevention","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2017.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}